EUCTR2008-003235-20-LT进行中（未招募）1 期
OPHO-ALL-2008 Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non B-ALL
- •2. Non Ph+ ALL
- •3. Age 1.0 - 17.9 years of age.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 160
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Bilineage ALL.
- •2. Pre-treatment with glucocorticosteroids or other antileukemic agents. Patients, who have been treated with systemic glucocorticosteroids or other anticancer agents (e.g. methotrexate or thiopurines) for more than a week prior to the diagnosis of ALL and initiation of antileukemic therapy, can be treated by the NOPHO ALL-2008 protocol and will be registered, but they cannot be included in the randomised trials.
- •3. Incomplete exploration for the risk group stratifying cytogenetic aberrations.
- •4. ALL predisposition syndromes. Patients with certain ALL-predisposing disorders (e.g. Down syndrome, Ataxia Telangiectasia) can be entered into the protocol with the amendments outlined in section 16, but can not be included in the randomised trials.
- •5. Previous cancer. Patients who have previously been treated for a malignant neoplasm can be treated by the NOPHO ALL-2008 protocol and will be registered, but they cannot be included in the randomised trials (see section 16). They will be treated according to the control arms of the protocol.
- •6. Intolerance to one or more anticancer agent.
- •7. Administration of additional chemotherapy during induction therapy for non-HR ALL. Patients with non-HR ALL, who at day 15 have a M3 bone marrow should not be given additional chemotherapy. If given, the patients will not be eligible for the SR-ALL treatment arm and the patient will not be eligible for randomisation.
- •8. Sexually active females not using contraception.
- •9. TPMT-deficiency (6MP-randomisation only).
- •10. DepoCyte during induction therapy (DepoCyte randomisation only)
研究者
相似试验
进行中（未招募）
1 期
OPHO-ALL-2008Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia - NOPHO-ALL-2008-1aAcute lymphoblastic leukemiaMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2008-003235-20-DKRigshospitalet1,000
进行中（未招募）
不适用
OPHO-ALL-2008Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia - NOPHO-ALL-2008-1aAcute lymphoblastic leukemiaMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2008-003235-20-SERigshospitalet1,000
进行中（未招募）
1 期
OPHO - ALL 2008. Treatment Protocol for Children (1.0 - 17.9 years of age) with Acute Lymphoblastic Leukemia - NOPHO ALL-2008AEUCTR2008-003235-20-ISandspítali Háskólasjúkrahús1,550
招募中
3 期
Protocol for treatment of children and adolescents with acute myeloid leukemia 0-18 yearsbloodcancer10024324leukemiaNL-OMON55459Västra Götalandregionen, Queen Silvias Childrens and Adolescents Hospital150
未知
不适用
A randomised controlled trial of high flow versus oxygen versus control in African children with severe pneumoniaISRCTN15622505Imperial College, London (UK)1,852